---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-102387"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:55:21.425213+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q2 net loss $38.9M ($0.35/sh); Gilead collab truncated

## Summary
- Net loss $38.9M ($0.35 per share) vs $25.6M ($0.24) in Q2 2024; revenue fell to $3.2M.
- Cash $180.8M; expects to fund operations into Q1 2027.
- Gilead collaboration research term trimmed from 7 to 5 yrs; $53.8M deferred revenue to be recognized in Q3 2025.
- First patients dosed in TNG462 combo with Revolution Medicines RAS(ON) inhibitors and TNG456 Phase 1/2.
- TNG462 monotherapy data expected 2H 2025; TNG260 clinical data also expected 2H 2025.

## SEC filing metadata
- accession: 0000950170-25-102387
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017025102387/0000950170-25-102387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017025102387/tngx-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-102387
- JSON: https://secwatch.observer/filing/0000950170-25-102387.json
- Plain text: https://secwatch.observer/filing/0000950170-25-102387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.